文献速递肿瘤 PET/CT

18F-氟代环丁烷羧酸PET/CT在前列腺癌患者中检出额外原发肿瘤

Detection of Additional Primary Neoplasms on 18F-Fluciclovine PET/CT in Patients with Primary Prostate Cancer.
PubMed 文献 · J Nucl Med · 2021-08-19

该研究回顾性分析了601例前列腺癌患者的663次18F-fluciclovine PET/CT检查,评估偶发第二原发肿瘤的检出率。55例(9.1%)发现疑似第二肿瘤,其中16例(2.7%)为PET/CT首次怀疑的偶发原发肿瘤,11例经组织学确诊,肾细胞癌最常见(45.5%)。

要点

  • 18F-fluciclovine PET/CT评估前列腺癌时,9.1%患者发现疑似第二肿瘤。
  • 2.7%患者为PET/CT首次怀疑的偶发原发肿瘤,其中11例经组织学确诊。
  • 组织学确诊的偶发原发癌中肾细胞癌最常见(45.5%)。

核心结论

  • 18F-fluciclovine PET/CT评估前列腺癌时,偶发第二原发肿瘤并不少见(9.1%),其中肾细胞癌最常见(45.5%)。
  • 由于该示踪剂具有广谱肿瘤显像能力,需仔细分析18F-fluciclovine PET/CT图像以检出偶发原发肿瘤。

研究设计与样本

  • 回顾性研究,纳入2016年8月至2021年4月间601例前列腺癌患者的663次临床18F-fluciclovine PET/CT检查(643次复发评估,20次初始分期)。
  • 分析影像报告和人口学数据,测定疑似第二肿瘤的最大SUV(SUVmax),并与临床和影像学结果关联以确定肿瘤性质。

主要发现

  • 16例(2.7%)为PET/CT首次怀疑的偶发原发肿瘤,3例提示脑膜瘤并经MRI证实。
  • 剩余13例中11例经组织学确诊恶性肿瘤,包括肾细胞癌(5/11;45.5%)、尿路上皮癌(2例)、多发性骨髓瘤、软骨肉瘤、皮肤鳞状细胞癌、食管鳞状细胞癌和肺癌(各1例,除1例同时患食管癌和肺癌)。
  • 组织学确诊恶性肿瘤中,透明细胞肾细胞癌摄取最低(SUVmax 3.4),皮肤鳞状细胞癌摄取最高(SUVmax 13.6)。
  • 2例无组织学确诊者中,1例经超声和MRI证实肾细胞癌,另1例孤立性肺结节疑似原发性肺癌并选择观察。

临床怎么用

  • 在前列腺癌患者行18F-fluciclovine PET/CT时,应仔细分析图像以检出可能的偶发第二原发肿瘤。

局限性

  • 本研究为回顾性研究。
  • 部分疑似偶发肿瘤缺乏组织病理学确诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to evaluate the detection rate of incidental second primary neoplasms in patients with prostate cancer on 18F-fluciclovine PET/CT. Methods: Imaging reports and patient demographic data were retrospectively reviewed from 663 clinical 18F-fluciclovine PET/CT studies, performed in 601 patients for the assessment of their prostate cancer (643 - recurrence evaluation, 20 - initial staging) from August 2016 to April 2021. Maximum SUV (SUVmax) of the suspected second neoplasms was determined. The results of 18F-fluciclovine PET/CT were correlated with clinical and radiologic studies to determine the nature of the suspected second neoplasms. Results: Fifty-five patients (9.1%) had findings suggestive of a second neoplasm. Thirty-nine of 55 had a known second neoplasm diagnosed before the PET/CT. An incidental second primary neoplasm was first suspected on 18F-fluciclovine PET/CT in 16 of 601 patients (2.7%). Three of the 16 patients had PET/CT suggestive of a meningioma that was corroborated on MRI. Of the remaining 13 patients, 11 had a tissue diagnosis confirming a malignancy. Second malignancies included renal cell carcinoma (RCC; 5/11; 45.5%), urothelial carcinoma (n = 2), multiple myeloma, chondrosarcoma, cutaneous squamous cell carcinoma, and squamous cell carcinoma of the esophagus and lung (n = 1, each; except for 1 patient with both esophageal and lung carcinomas). Among histopathologically confirmed malignancies, clear-cell RCC had the lowest uptake (SUVmax 3.4), and cutaneous squamous cell carcinoma had the highest uptake (SUVmax 13.6). Of the 2 patients with no histopathologic confirmation, 1 had ultrasound and MRI findings corroborating the diagnosis of RCC. The other patient had a solitary lung nodule suggestive of primary lung carcinoma and elected to undergo observation. Conclusion: Incidental findings consistent with a second primary neoplasm are not infrequently seen on 18F-fluciclovine PET/CT performed for assessment of prostate cancer (9.1%). Of the incidentally detected primary cancers, RCC was the most common (45.5%). These findings indicate the need for a careful analysis of 18F-fluciclovine PET/CT images, due to the broad tumor imaging capabilities of this radiotracer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Parihar AS, Schmidt LR, Dehdashti F, et al. Detection of Additional Primary Neoplasms on 18F-Fluciclovine PET/CT in Patients with Primary Prostate Cancer. J Nucl Med. 2021. PMID: 34413144. doi:10.2967/jnumed.121.262647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。